Previous 10 | Next 10 |
home / stock / nvo / nvo articles
After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company (NYSE:LLY) stock h...
Novo Nordisk A/S (NYSE:NVO) has reportedly warned, indicating that starter kits for its widely used diabetes drug Ozempic (semaglutide) will n...
Costco Wholesale Corporation (NASDAQ:COST) has launched a weight management program to help its members in their weight loss journey. The program w...
Citi Research has increased the price target for Eli Lilly And Co (NYSE:LLY), reflecting increased anticipated risk-adjusted peak sa...
Sen. Bernie Sanders (I-Vt.) has taken a stand against the "outrageous" prices of diabetes drug Ozempic by Novo Nordisk (NYSE:NVO). He is considerin...
The first quarter of 2024 has turned out to be a blockbuster for most asset classes, and the strong performances have left investors worried abou...
The first quarter of 2024 has turned out to be a blockbuster for most asset classes, and the strong performances have left investors worried abou...
Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key pr...
A recent study suggests that despite Novo Nordisk A/S’s (NYSE:NVO) high monthly charge of close to $1,000 for its blockbuster diabe...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...